文献速递湿疹皮炎与荨麻疹

芦可替尼乳膏治疗2-11岁儿童特应性皮炎的52周安全性与疾病控制:TRuE-AD3 III期研究结果

52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study.
PubMed 文献 · J Am Acad Dermatol · 2026-10-30

TRuE-AD3 III期研究纳入2-11岁轻中度特应性皮炎患儿,先随机接受芦可替尼乳膏0.75%或1.5%或赋形剂治疗8周,随后芦可替尼组继续按需外用至52周,赋形剂组重新随机至芦可替尼乳膏两种浓度按需使用。长期安全性期间未出现新安全信号,应用部位反应发生率1.1%,无严重治疗相关不良事件;初始芦可替尼组第52周疾病控制得以维持。

要点

  • 芦可替尼乳膏按需外用44周在2-11岁患儿中耐受良好,无新安全信号。
  • 应用部位反应发生率1.1%,未观察到严重治疗相关不良事件。
  • 初始芦可替尼组第52周IGA 0/1应答率0.75%组79.5%、1.5%组72.3%。

核心结论

  • 芦可替尼乳膏按需外用44周在2-11岁轻中度特应性皮炎患儿中耐受良好并显示疾病控制,结果与青少年和成人一致。

研究设计与样本

  • III期TRuE-AD3研究:2-11岁轻中度特应性皮炎患儿先随机接受芦可替尼乳膏0.75%或1.5%或赋形剂治疗8周,随后芦可替尼组继续按需每日两次外用至52周,赋形剂组重新随机至芦可替尼乳膏两种浓度按需使用。

主要发现

  • 长期安全性期间接受芦可替尼乳膏治疗的患儿(N=282)未出现新安全信号。
  • 应用部位反应发生率为1.1%,未观察到严重治疗相关不良事件。
  • 初始随机至芦可替尼乳膏0.75%/1.5%的患者第52周IGA 0/1分别为79.5%/72.3%,受累体表面积分别为2.0%/1.9%。

关键数值与推荐

  • 第52周疾病控制维持:初始芦可替尼乳膏0.75%组IGA 0/1为79.5%,1.5%组为72.3%。
  • 第52周受累体表面积:初始芦可替尼乳膏0.75%组为2.0%,1.5%组为1.9%。

临床怎么用

  • 支持芦可替尼乳膏按需每日两次外用作为2-11岁轻中度特应性皮炎患儿的长期治疗选择。

局限性

  • 长期安全性期间无赋形剂对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ruxolitinib (selective Janus kinase [JAK]1/JAK2 inhibitor) cream demonstrated efficacy and safety vs vehicle during 8 weeks of continuous use in a phase 3 study of children with atopic dermatitis (AD). OBJECTIVE: To evaluate long-term safety (LTS) and disease control with as-needed ruxolitinib cream use in children. METHODS: Children aged 2-11 years with mild-to-moderate AD initially randomized to ruxolitinib cream (0.75% or 1.5%) in the 8-week study continued the same twice-daily (BID) regimen for an additional 44 weeks but only applied cream as needed BID; patients initially on vehicle were rerandomized (1:1) to apply either ruxolitinib cream strength as needed. Safety and disease control were assessed. RESULTS: No new safety signals emerged among children who applied ruxolitinib cream in the LTS period (N=282). Application site reactions were infrequent (1.1%), and no serious treatment-related adverse events were observed. Among patients initially randomized to ruxolitinib cream (0.75%/1.5%), disease control was maintained to Week 52 (Investigator's Global Assessment score 0/1, 79.5%/72.3%; affected body surface area, 2.0%/1.9%). LIMITATIONS: No vehicle control in LTS period. CONCLUSION: Ruxolitinib cream applied as needed over 44 weeks was well tolerated and demonstrated disease control in children aged 2-11 years, consistent with findings in adolescents and adults.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Paller AS, Stein Gold LF, Simpson EL, et al. 52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study. J Am Acad Dermatol. 2026. PMID: 42962926. doi:10.1016/j.jaad.2026.10.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。